Doxorubicin nanoparticles - Onxeo

Drug Profile

Doxorubicin nanoparticles - Onxeo

Alternative Names: BA-003; Doxorubicin Transdrug; Doxorubicin-Transdrug; Livatag

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioAlliance Pharma
  • Developer CNRS; Onxeo SA
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Hepatocellular carcinoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 26 Oct 2017 Discontinued - Clinical-Phase-Unknown for Hepatocellular carcinoma (Combination therapy, First-line therapy) (IV)
  • 26 Oct 2017 Discontinued - Phase-II/III for Hepatocellular carcinoma in European Union (Intra-arterial)
  • 26 Oct 2017 Discontinued - Phase-III for Hepatocellular carcinoma (Late-stage disease, Second-line therapy or greater) in Saudi Arabia, Turkey, Spain, Lebanon, Italy, Hungary, Germany, France, Egypt, Belgium, Austria, USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top